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Volume 57, Number 5S Abstracts 99Soccluded (OMA) LEB. Variables identiﬁed on univariate
analysis (inclusion threshold P < .08) were included in
a multivariable logistic regression model to identify inde-
pendent predictors.
Results: Of 1404 LEB patients, 162 (11.5%) had MA,
89 (6.3%) with patent and 73 (5.2%) with occluded LEB.
For PMA, 21 (23.6%) had critical graft stenosis, of which
17 (81.0%) underwent revision, with mean time to revision
of 50.76 days (SD 6 55.49). Minority race (OR, 2.69;
CI, 1.28-5.66; P ¼ .0092), diabetes (OR, 4.14; CI,
1.20-14.24; P ¼ .025), lower baseline activity score (OR,
1.92; CI, 1.24-2.98; P ¼ .0036), and negative change in
3-month activity (OR, 1.61; CI, 1.22-2.13; P ¼ .0007)
were predictors for PMA, while tissue loss was not predic-
tive (OR, 2.32; CI, 0.66-8.08; P ¼ .19).
For OMA, 64 (87.7%) had critical graft stenosis but
only 35 (54.7%) underwent revision, with mean time to
revision of 76.11 days (SD 6 80.14) and mean time to
MA of 107.37 days (SD 6 103.39).
Conclusions: PMA patients had lower rates of graft
stenosis, but were revised earlier than their OMA counter-
parts. Non-graft-related factors (demographic and func-
tional activity) also inﬂuenced PMA. Further investigation
into PMA may optimize treatment decisions.
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Objectives: To evaluate long term outcomes and sac
volume (SV) shrinkage after endovascular popliteal artery
aneurysm repair (EVPAR).
Methods: A retrospective review of EVPAR cases per-
formed between January 1999 and December 2012. SV
shrinkage, long term patency, limb salvage (LS), and
survival (S) were evaluated with K-M estimates. Anatomical
characteristics and clinical presentation were evaluated for
their association with patency using multiple logistic
regression.
Results: 46 EVPAR procedures in 42 patients. Mean
age was 68 yr, 86% were male; mean SV 42 6 12 cm3.
Elective repair in 91% of cases, while 9% treated for rupture
or thrombosis; 56% were asymptomatic, 35% had claudica-
tion and 9% rest pain. Technical success was 98%. At mean
follow-up of 84 months (range, 6 to 138 months) primary,
assisted primary, and secondary patency was 63%, 68%, and
68%; LS was 96% and S 81%. Of the 13 limbs with stent
graft failure, seven required conversion, two underwent
amputation, while four remained with mild claudication.
Of those with graft occlusion, 61% (8 out of 13) of cases
occurred within the ﬁrst year of follow-up. The overall
mean difference in aneurysm SV shrinkage at 7 years was
signiﬁcant (42 6 12 cm3 vs 21 6 8 cm3; P ¼ .02). Theassociation of covering a length >20 cm and distal landing
zone between 1 and 1.5 cm from the take off of the ante-
rior tibial artery (ATA) was a negative predictor for
improved patency (OR, 3.05; 95% CI, 1.9 to 2.3; P ¼
.005).
Conclusions: EVPAR provides successful aneurysm
exclusion with acceptable long term patency, excellent LS
and S. However, close surveillance is required, particularly
within the ﬁrst postoperative year. Patients requiring
coverage >20 cm and a distal landing zone between 1
and 1.5 cm from the ATA may be at increased risk for
failure.
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Objectives: Bone marrow aspirate injections (BMA) in
the treatment of patients with critical limb ischemia (CLI)
is a potential treatment option in poor candidates for stan-
dard revascularization procedures. While clinical trials are
ongoing, there is little comparative data to assess its efﬁcacy
compared to bypass.
Methods: 19 patients with poor revascularization
options underwent BMA. Outcomes were compared to
a cohort of 42 CLI patients undergoing infrainguinal
bypass felt to be at high risk for graft failure (previous
endovascular treatment or bypass, tibial target, and tissue
loss). BMA patients underwent harvest of 120-240 mL of
